Gene Editing [2026]: What CRISPR Has Actually Delivered

CRISPR-Cas9 gene editing went from scientific curiosity to Nobel Prize (Jennifer Doudna and Emmanuelle Charpentier, 2020) to approved medical therapy faster than almost any previous biotechnology. The first CRISPR-based therapy received FDA approval in December 2023 — Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease and beta thalassemia. Eight years after CRISPR's therapeutic potential was first demonstrated in cell experiments, it is now a clinical reality. Here is the honest assessment of what this means and what remains ahead.

What Has Actually Been Achieved

Casgevy's approval for sickle cell disease is a genuine milestone. Sickle cell disease — caused by a single mutation in the gene encoding hemoglobin — affects approximately 100,000 Americans and millions more globally, primarily of African descent. The treatment involves extracting a patient's own blood stem cells, editing them to reactivate fetal hemoglobin production (which is suppressed in adults but can compensate for the sickle cell mutation), and reinfusing the edited cells. In clinical trials, 29 of 29 patients with severe sickle cell disease who received Casgevy and were followed for at least 12 months experienced no vaso-occlusive crisis — the painful and potentially life-threatening episodes that characterize the disease.

These are remarkable results for a disease that previously had no cure (bone marrow transplant was curative but required a matched donor and carried significant transplant risk). The qualification: the treatment is extraordinarily expensive — Vertex priced Casgevy at $2.2 million for a one-time treatment — and requires chemotherapy to prepare the patient's bone marrow for the edited cells, which carries its own significant side effects. Accessibility for the global population most affected by sickle cell disease (in Sub-Saharan Africa) remains essentially zero at current pricing.

What's in the Pipeline

Beyond sickle cell disease, CRISPR therapies are in various stages of development for: other inherited blood disorders (beta thalassemia, already included in Casgevy's approval), Duchenne muscular dystrophy (clinical trials showing early promise), Leber congenital amaurosis (a form of inherited blindness, with early clinical results), various cancers (using CRISPR to engineer immune cells to target tumors), and high cholesterol (editing liver genes to reduce LDL production).

The cancer immunotherapy applications are particularly active. CRISPR-edited CAR-T cells — immune cells engineered to recognize and attack specific cancer types — are in multiple clinical trials. The early results are mixed: some patients have shown dramatic responses, others haven't responded. The challenge is making the therapy work reliably across diverse patient populations rather than spectacularly in exceptional cases.

The Safety Questions

The primary safety concern with CRISPR editing is off-target effects — the Cas9 enzyme making cuts at genomic locations other than the intended target. Early CRISPR systems had significant off-target cutting rates that would be unacceptable in therapeutic applications. Subsequent advances — higher-fidelity Cas9 variants, base editors that change single DNA letters without making double-strand cuts, and prime editors that can make a wider range of precise edits — have substantially reduced off-target effects, but not eliminated them entirely. The long-term safety monitoring of patients who received early CRISPR therapies will be important for establishing whether off-target edits produce any adverse effects over decades.

Germline editing — making genetic changes in embryos that would be inherited by future generations — remains both technically feasible and ethically and legally restricted in most countries following the 2018 controversy when Chinese scientist He Jiankui created the first gene-edited human babies, editing an HIV-resistance gene into twin embryos. He Jiankui was imprisoned; the scientific community's response was nearly universal condemnation. The distinction between somatic editing (affecting only the treated patient) and germline editing (heritable) is the key ethical boundary that current therapeutic applications respect.

Honest Bottom Line: Casgevy's 2023 FDA approval for sickle cell disease is a genuine milestone — 29 of 29 trial patients experienced no severe disease episodes during follow-up. The $2.2 million price tag makes it currently inaccessible to most of the world's sickle cell population. The CRISPR pipeline includes blood disorders, muscular dystrophy, inherited blindness, and cancer immunotherapy, with mixed early results across applications. Off-target editing effects have been substantially reduced by improved tools but not eliminated — long-term safety monitoring of treated patients remains important. Germline editing remains ethically and legally restricted following the He Jiankui controversy.